EyeCo

Eye Co is an Australian clinical-stage biotechnology company focused on developing anti-inflammatory therapeutics for sight-threatening retinal diseases. The company's lead candidate is Alvizon (fludrocortisone acetate), a synthetic corticosteroid with both mineralocorticoid and glucocorticoid properties, being developed as an intravitreal injection for Geographic Atrophy (GA) associated with dry age-related macular degeneration (AMD). Eye Co's approach targets the chronic inflammation and blood-retinal barrier dysfunction underlying retinal degeneration, aiming to provide a more effective and safer alternative to existing treatments. The company is currently advancing Alvizon through Phase 2 clinical trials and exploring its potential in combination with anti-VEGF therapies for other retinal vascular conditions.